1,064 results on '"Phillips, Elizabeth J."'
Search Results
2. Multiomic single-cell sequencing defines tissue-specific responses in Stevens-Johnson syndrome and toxic epidermal necrolysis
3. Severe cutaneous adverse reactions
4. T cells specific for α-myosin drive immunotherapy-related myocarditis
5. A Skin Testing Strategy for Non–IgE-Mediated Reactions Associated With Vancomycin
6. First-Line Antituberculosis Drug Challenge Reactions in Drug Reaction With Eosinophilia and Systemic Symptoms Syndrome in an HIV Endemic Setting
7. Improving Clinical Practice Through Patient Registries in Allergy and Immunology
8. Patient-Reported Outcome Measures in Food and Drug Allergy
9. Evaluation of cephalosporin allergy: Survey of drug allergy experts
10. Delayed Skin Testing for Systemic Medications: Helpful or Not?
11. A systematic review and expert Delphi Consensus recommendation on the use of vaccines in patients receiving dupilumab: A position paper of the American College of Allergy, Asthma and Immunology
12. The Australasian Registry for Severe Cutaneous Adverse Reactions (AUS-SCAR) – Providing a roadmap for closing the diagnostic, patient, and healthcare gaps for a group of rare drug eruptions
13. Drug-induced hypersensitivity syndrome/drug reaction with eosinophilia and systemic symptoms. Part I. Epidemiology, pathogenesis, clinicopathological features, and prognosis
14. Drug-induced hypersensitivity syndrome/drug reaction with eosinophilia and systemic symptoms. Part II diagnosis and management
15. Development of anti-PEG IgG/IgM/IgE ELISA assays for profiling anti-PEG immunoglobulin response in PEG-sensitized individuals and patients with alpha-gal allergy
16. Vancomycin-Induced Liver Injury, DRESS, and HLA-A∗32:01
17. Association between atopic dermatitis, autoimmune illnesses, Epstein-Barr virus, and cytomegalovirus
18. Association of KIR2DL5, KIR2DS5, and KIR2DS1 allelic variation and atopic dermatitis
19. United States Drug Allergy Registry (USDAR) grading scale for immediate drug reactions
20. Drug Allergy in Women
21. An Update in COVID-19 Vaccine Reactions in 2023: Progress and Understanding
22. Updated guidance regarding the risk of allergic reactions to COVID-19 vaccines and recommended evaluation and management: A GRADE assessment and international consensus approach
23. Identifying and Managing Those at Risk for Vaccine-Related Allergy and Anaphylaxis
24. Drug Allergy Practice Parameter Updates to Incorporate Into Your Clinical Practice
25. Clinical Phenotypes of Immediate First-Dose Reactions to mRNA COVID-19: A Multicenter Latent Class Analysis
26. Laboratory and demographic predictors of functional assay positive status in suspected heparin-induced thrombocytopenia: A multicenter retrospective cohort study
27. Advances in the Understanding of Drug Hypersensitivity: 2012 Through 2022
28. Allergy Electronic Health Record Documentation: A 2022 Work Group Report of the AAAAI Adverse Reactions to Drugs, Biologicals, and Latex Committee
29. Adverse Events and Safety of SARS-CoV-2 Vaccines: What’s New and What’s Next
30. Genome-wide association study of platelet factor 4/heparin antibodies in heparin-induced thrombocytopenia
31. ABO O blood group as a risk factor for platelet reactivity in heparin-induced thrombocytopenia
32. Practical Implementation of Genetics: New Concepts in Immunogenomics to Predict, Prevent, and Diagnose Drug Hypersensitivity
33. Immediate and Delayed Hypersensitivity Reactions to Beta-Lactam Antibiotics
34. Applying lessons learned from nanomedicines to understand rare hypersensitivity reactions to mRNA-based SARS-CoV-2 vaccines
35. Standards for practical intravenous rapid drug desensitization & delabeling: A WAO committee statement
36. Garcinia cambogia, Either Alone or in Combination With Green Tea, Causes Moderate to Severe Liver Injury
37. Recognizing Drug Hypersensitivity in Pigmented Skin
38. Drug-Induced Hypersensitivity Syndrome (DIHS)/Drug Reaction With Eosinophilia and Systemic Symptoms (DRESS): Clinical Features and Pathogenesis
39. PheMIME: an interactive web app and knowledge base for phenome-wide, multi-institutional multimorbidity analysis.
40. HLA-B*07:02 and HLA-C*07:02 are associated with trimethoprim-sulfamethoxazole respiratory failure
41. Abacavir inhibits but does not cause self-reactivity to HLA-B*57:01-restricted EBV specific T cell receptors
42. Integrating gene expression and clinical data to identify drug repurposing candidates for hyperlipidemia and hypertension
43. Use of Vaccines in Patients Receiving Dupilumab, A Systematic Review and Expert Delphi Consensus Recommendation: A position paper of the American College of Allergy, Asthma and Immunology
44. Drugs associated with serum sickness and serum sickness–like reactions: A review of FDA Adverse Event Reporting System (FAERS) data
45. Rituximab Therapy for Insulin Allergy in Type-1 Diabetes Mellitus
46. Hidden Dangers: Recognizing Excipients as Potential Causes of Drug and Vaccine Hypersensitivity Reactions
47. Advances in immunoglobulin E mediated antibiotic allergy
48. The Role of In Vivo and Ex Vivo Diagnostic Tools in Severe Delayed Immune-Mediated Adverse Antibiotic Drug Reactions
49. Skin testing and challenge in patients with immediate hypersensitivity reactions to gadolinium-based contrast agents identify safe future options
50. Emerging Causes of Drug-Induced Anaphylaxis: A Review of Anaphylaxis-Associated Reports in the FDA Adverse Event Reporting System (FAERS)
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.